We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Drugmaker praises country’s scientific expertise but says it must address conflicts in areas such as drug pricing
Doubts grow over safety and effectiveness of drugs that were marketed as coronavirus treatments
Big-selling molnupiravir treatment produces permanent mutations that can be passed from patient to patient
Expensive medicines made by Pfizer, J&J and Merck selected for talks in biggest shake-up in decades
Pharmaceutical group says parts of law are unconstitutional
Pharmaceutical giant has good reason to gamble on acquisition before blockbuster drug loses its patent protection
Pharmaceutical and biotech deals are rebounding after a dip last year
Industry rejects call for transparency over use of strategy that can delay competition from generic medicines
From obesity drugs to cancer treatments, this year should be remembered for pharmaceutical advances
Results of UK study show drug cuts symptom duration by about 4 days but does not reduce deaths
Study suggests combination with Merck immunotherapy drug reduces risk of death in high-risk patients
UK trial shows ‘no difference’ between taking molnupiravir or placebo in reducing clinical admissions during Omicron wave
Chief financial officer says drugmaker complies with law amid congressional probe
Tie-up faces obstacles in current climate of aggressive watchdogs and concern over drug prices
US group attracted by approved drugs as it prepares to lose patent protection of Keytruda
EMA said to be unlikely to grant marketing authorisation to molnupiravir this month after ‘problematic’ data
Concerns grow over molnupiravir’s ability to reduce Covid hospitalisations and deaths
Executive says patients on other medications will not be able to take competing antiviral treatment
Experts advising FDA recommend treatment for high-risk patients amid fears over Omicron variant
Full analysis of trial results shows molnupiravir had a risk reduction of 30%
New medicines from Pfizer and Merck could take some pressure off hospitals. But will they work on the already vaccinated?
First authorisation for antiviral drug that halves risk of hospitalisation or death
Move contrasts with mRNA makers Pfizer and Moderna, which have rejected sharing vaccine technology
Molnupiravir has limitations but drugmakers should be able to build on it to create other treatments
Drugmaker seeks authorisation from FDA for oral treatment shown to prevent severe disease in vulnerable people
International Edition
